ResMed Net Worth
ResMed Net Worth Breakdown | RMD |
ResMed Net Worth Analysis
ResMed's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including ResMed's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of ResMed's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform ResMed's net worth analysis. One common approach is to calculate ResMed's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares ResMed's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing ResMed's net worth. This approach calculates the present value of ResMed's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of ResMed's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate ResMed's net worth. This involves comparing ResMed's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into ResMed's net worth relative to its peers.
Enterprise Value |
|
To determine if ResMed is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ResMed's net worth research are outlined below:
| ResMed Inc has a strong financial position based on the latest SEC filings | |
| About 65.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: ResMed Up 4 percent Since Last Earnings Report Can It Continue |
ResMed Quarterly Good Will |
|
ResMed uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ResMed Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ResMed's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 25th of April 2024 Upcoming Quarterly Report | View | |
| 1st of August 2024 Next Financial Report | View | |
| 31st of March 2024 Next Fiscal Quarter End | View | |
| 1st of August 2024 Next Fiscal Year End | View | |
| 31st of December 2023 Last Quarter Report | View | |
| 30th of June 2023 Last Financial Announcement | View |
Know ResMed's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ResMed is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ResMed Inc backward and forwards among themselves. ResMed's institutional investor refers to the entity that pools money to purchase ResMed's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2025-03-31 | 955.3 K | Dimensional Fund Advisors, Inc. | 2025-03-31 | 793.8 K | Los Angeles Capital Management Llc | 2025-03-31 | 773.2 K | Barclays Plc | 2025-03-31 | 740.4 K | Goldman Sachs Group Inc | 2025-03-31 | 739 K | Nordea Investment Mgmt Bank Demark A/s | 2025-03-31 | 732.2 K | Amundi | 2025-03-31 | 631.1 K | Jpmorgan Chase & Co | 2025-03-31 | 568.8 K | Marshall Wace Asset Management Ltd | 2025-03-31 | 556.4 K | Vanguard Group Inc | 2025-03-31 | 18.5 M | Blackrock Inc | 2025-03-31 | 12.7 M |
Follow ResMed's market capitalization trends
The company currently falls under 'Large-Cap' category with a total capitalization of 35.61 B.Market Cap |
|
Project ResMed's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.26 | 0.27 | |
| Return On Capital Employed | 0.20 | 0.14 | |
| Return On Assets | 0.13 | 0.10 | |
| Return On Equity | 0.19 | 0.14 |
When accessing ResMed's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures ResMed's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ResMed's profitability and make more informed investment decisions.
Please note, the presentation of ResMed's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ResMed's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of ResMed's management manipulating its earnings.
Evaluate ResMed's management efficiency
ResMed Inc has Return on Asset of 0.1401 % which means that on every $100 spent on assets, it made $0.1401 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2581 %, implying that it generated $0.2581 on every 100 dollars invested. ResMed's management efficiency ratios could be used to measure how well ResMed manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.27, whereas Return On Capital Employed is forecasted to decline to 0.14. At present, ResMed's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 555.2 M, whereas Net Tangible Assets are forecasted to decline to about 632.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 29.78 | 31.26 | |
| Tangible Book Value Per Share | 9.40 | 9.87 | |
| Enterprise Value Over EBITDA | 16.50 | 14.82 | |
| Price Book Value Ratio | 5.09 | 4.77 | |
| Enterprise Value Multiple | 16.50 | 14.82 | |
| Price Fair Value | 5.09 | 4.77 | |
| Enterprise Value | 429.5 M | 451 M |
ResMed Inc has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 7.0724 | Revenue | Quarterly Revenue Growth 0.079 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ResMed insiders, such as employees or executives, is commonly permitted as long as it does not rely on ResMed's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ResMed insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ResMed Corporate Filings
F4 | 22nd of May 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 23rd of April 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 10th of March 2025 Other Reports | ViewVerify |
ResMed Earnings per Share Projection vs Actual
ResMed Corporate Directors
| Ronald Taylor | Lead Independent Director | Profile | |
| Harjit Gill | Independent Director | Profile | |
| Carol Burt | Independent Director | Profile | |
| Jan Witte | Independent Director | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ResMed. If investors know ResMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ResMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.216 | Dividend Share 2.07 | Earnings Share 8.91 | Revenue Per Share | Quarterly Revenue Growth 0.079 |
The market value of ResMed Inc is measured differently than its book value, which is the value of ResMed that is recorded on the company's balance sheet. Investors also form their own opinion of ResMed's value that differs from its market value or its book value, called intrinsic value, which is ResMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ResMed's market value can be influenced by many factors that don't directly affect ResMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ResMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if ResMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.